Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
Date:4/28/2011

SOUTH SAN FRANCISCO, Calif., April 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 13th International Myeloma Workshop (IMW), May 3-6, 2011, in Paris, France.

"The data we are accumulating for carfilzomib continues to support its potential as an important new treatment option for patients with multiple myeloma.  Data from several studies will be presented at the upcoming IMW meeting, including interim data in newly diagnosed patients from a Multiple Myeloma Research Consortium study being led by Dr. Andrzej Jakubowiak at the University of Michigan Comprehensive Cancer Center that is evaluating carfilzomib in combination with a standard therapy," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. "Onyx is committed to bringing this promising therapy to patients as quickly as possible and remains on track for filing a new drug application with the U.S. Food and Drug Administration as early as mid-year under the accelerated approval process.  We are also actively enrolling patients in the Phase 3 FOCUS trial for the treatment of patients with relapsed and refractory myeloma to support a filing with the European Medicines Agency, as well as, in the Phase 3 ASPIRE trial in relapsed multiple myeloma."

Carfilzomib data highlights include:

Carfilzomib and other new proteasome inhibitors: Clinical data

  • Andrzej Jakubowiak, M.D., Ph.D., University of Michigan Comprehensive Cancer Center, USA
  • Thursday, May 5, 2011, 14:19 – 14:31
  • Oral Session Name: Plenary Session I: New Drugs and Therapeutic Approaches

Results of PX-171
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2011 Financial Results on May 5, 2011
2. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
3. Amylin Pharmaceuticals to Present at the Deutsche Bank 36th Annual Healthcare Conference
4. Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
6. Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress
7. Reportlinker Adds The Outlook for Pharmaceuticals in Latin America
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2011
9. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
10. Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011
11. Cumberland Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... SAN FRANCISCO, Calif. , May 28, 2015 /PRNewswire/ ... treatment of cancer, today announced that Sean McCarthy ... the upcoming Jefferies 2015 Global Healthcare Conference ... p.m. EDT on Tuesday, June 2, 2015. Dr. McCarthy ... the company,s Precision cancer immunotherapy and Probody drug conjugate ...
(Date:5/28/2015)... 28, 2015  Shareholder rights law firm Robbins ... officers and directors of Eleven Biotherapeutics, Inc. (NASDAQGM: EBIO) ... is a clinical-stage biopharmaceutical company that engages in ... treat eye diseases, primarily in the ... this press release on the law firm,s Shareholder ...
(Date:5/28/2015)... Eli Lilly and Company (NYSE: LLY ) and Incyte ... June 11 to discuss data from the first two pivotal ... two trials, RA-BEACON and RA-BUILD, will be presented on June ... in Rome, Italy . The ... Time. The live audio webcast can be accessed through a ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3
(Date:5/28/2015)... Texas (PRWEB) May 28, 2015 Park Cities ... Group Dog Training class starting Saturday, June 6th ... the courtyard of 5831 McCommas Blvd in Dallas, with a ... classes will run for five weeks, with no class being ... the class is $135. , In this Intermediate-to-Advanced level class, ...
(Date:5/28/2015)... Three years ago, Dr. Jeffrey Gosin announced ... Vascular & Vein Center! Dr. Gosin’s center is ... is his mission to provide the highest quality care in ... Dr. Jeffrey Gosin is Board Certified in Surgery and Vascular ... and Jefferson Medical College. He completed a General Surgery residency ...
(Date:5/28/2015)... May 28, 2015 AMVETS leaders this ... prize winner Robert Davis of Newark, Del. AMVETS National ... him on winning the $10,000 sweepstakes grand prize. , ... 100,000 entries from around the country for prizes ranging ... took place on May 21 at the AMVETS National ...
(Date:5/28/2015)... Medelis, Inc., a specialty oncology CRO , ... the role of president. , “ Bill Taaffe has ... said Larry Flanagan, Medelis’ CEO and co-founder. “He will be ... phase of growth.” , Taaffe joined ICON’s U.S. clinical ... to over 4,500 employees, achieving 12 consecutive years of growth ...
(Date:5/28/2015)... 28, 2015 ISMETT , a leading ... boosted the Sicilian economy by €132.5 million in expenditure in ... of more than €73 million by retaining patients who otherwise ... a new study by the Battelle Memorial Institute. At the ... training and advanced health care management that is transforming Sicily ...
Breaking Medicine News(10 mins):Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 2Health News:Dr. Jeffrey Gosin is Celebrating Three Years at his Somers Point Location! 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Bill Taaffe, Former President and CEO of ICON Clinical Research-US, Joins Medelis, a Specialty Oncology CRO, in the Role of President 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 2Health News:UPMC-Managed Transplant Hospital Drives Major Economic Benefits for Sicily, Study Finds 3
... Holohan HealthDay Reporter , WEDNESDAY, Jan. 5 (HealthDay ... of chickenpox-related hospitalizations in the United States for the first ... And a second study has found that the ... Centers for Disease Control and Prevention in 2006, may offer ...
... doses of the varicella, or chickenpox, vaccine provide excellent protection ... severe disease. To be published in the February 1 issue ... support the two-dose vaccine regimen recommended in the United States ... study online.) The Centers for Disease Control and Prevention ...
... HealthDay Reporter , TUESDAY, Jan. 4 (HealthDay News) -- Up ... an increase that translates into many fewer injuries and deaths ... the first state law requiring seat belts was passed in ... But now, according to the U.S. Centers for Disease Control ...
... HealthDay Reporter , TUESDAY, Jan. 4 (HealthDay News) -- ... of the drug Avastin to treat breast cancer, a new ... odds of congestive heart failure in these patients. The ... Clinical Oncology , included almost 4,000 patients and found a ...
... DURHAM, N.C. A tiny light source and sensors at ... way to identify pre-cancerous cells in the lining of the ... successfully tested on patients during a clinical trial at the ... the promise of being a less invasive method for testing ...
... there is often concern about possible effects on the ... birth defects (thalidomide being a notorious example), and others ... about most drugs, level of risk. Researchers in the ... preclinical model for predicting a drug,s teratogenicity (tendency to ...
Cached Medicine News:Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 2Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 3Health News:Chickenpox Vaccine Cuts Hospitalization Rates: Study 4Health News:Study confirms 2 vaccine doses protect children from chickenpox 2Health News:Six Out of 7 Drivers Use Seat Belts: CDC 2Health News:Six Out of 7 Drivers Use Seat Belts: CDC 3Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 2Health News:More Evidence Links Avastin to Heart Failure in Breast Cancer Patients 3Health News:Detecting esophageal cancer with light 2Health News:Model predicts a drug's likelihood of causing birth defects 2
... The Techne TC-512 has a graphical touch ... your experiments at the "touch of a ... Wide linear gradient, Touch Screen, Graphical Display, ... Performance, Versatile Block Format, Intuitive Programmin, Free ...
... Techne TC412 is a high performance, high sample ... Features & Benefits include: Flexible block format, ... 8 peltiers, PC networking. Includes a four ... 32 Techne cyclers can be connected and run ...
... a compact design for personal use, yet is able ... up to 32 samples simultaneously. It contains a heating ... to add mineral oil to prevent evaporation of the ... and up to 15 steps can be freely connected ...
... cycler is the smallest footprint two-bay thermal ... ever before. The Disciple instrument ... communications to a computer using a remote ... thermal cycler contains the latest in power ...
Medicine Products: